Fig S1 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Year: 2023
Type: other
Abstract: Fig S1. A. Treatment duration and clinical events for four subjects with clinical benefit. In the swimmer plot, patients are deceased at last follow-up unless indicated by the arrowhead. Abbreviations: LMS - leiomyosarcoma; UTUC - upper tract urothelial carcinoma; SCC - squamous cell carcinoma. B-C. Kaplan Meier curves for progression-free survival (B) and overall survival (C).
Authors: Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361939130